Nell Beattie Biography and Net Worth

Insider of VBI Vaccines

Ms. Beattie joined VBI in 2015 after completing her M.B.A at the Tuck School of Business at Dartmouth College. Prior to receiving her M.B.A., she was a consultant at Artisan Healthcare Consulting, where she worked with pharmaceutical and biotechnology companies to develop financial and strategic analyses, as well as provided guidance and support for corporate and business development efforts. Ms. Beattie also holds a B.A. from Dartmouth College.

What is Nell Beattie's net worth?: The estimated net worth of Nell Beattie is at least $0.00 as of October 1st, 2019. Ms. Beattie owns 3,000 shares of VBI Vaccines stock worth more than $0 as of November 24th. This net worth evaluation does not reflect any other investments that Ms. Beattie may own. Learn More about Nell Beattie's net worth.
How old is Nell Beattie?: Ms. Beattie is currently 36 years old. There are 7 older executives and no younger executives at VBI Vaccines. The oldest executive at VBI Vaccines is Dr. Francisco Diaz-Mitoma FRCPC, M.D., Ph.D., Chief Medical Officer, who is 69 years old. Learn More on Nell Beattie's age.
How do I contact Nell Beattie?: The corporate mailing address for Ms. Beattie and other VBI Vaccines executives is 222 Third Street Suite 2241, Cambridge MA, 02142. VBI Vaccines can also be reached via phone at (617) 830-3031 and via email at [email protected]. Learn More on Nell Beattie's contact information.
Has Nell Beattie been buying or selling shares of VBI Vaccines?: Nell Beattie has not been actively trading shares of VBI Vaccines in the last ninety days. Most recently, on Friday, December 3rd, Nell Beattie bought 410 shares of VBI Vaccines stock. The stock was acquired at an average cost of $49.00 per share, with a total value of $20,090.00. Learn More on Nell Beattie's trading history.

Nell Beattie Insider Trading History at VBI Vaccines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2021	Buy	410	$49.00	$20,090.00
10/1/2019	Buy	500	$9.60	$4,800.00	3,000
6/19/2019	Buy	400	$14.80	$5,920.00	2,500
8/3/2018	Buy	100	$40.20	$4,020.00	1,037

Nell Beattie Buying and Selling Activity at VBI Vaccines

VBI Vaccines Company Overview

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

Today's Range

Now: N/A

50 Day Range

MA: $0.23

$0.02

$0.79

2 Week Range

Now: N/A

Volume

29,900,200 shs

Average Volume

3,655,737 shs

Market Capitalization

$1.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW